Cantuzumab ravtansine-1 mg

Description

Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Robert J. Lutz, et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Res (2005) 65 (9_Supplement): 334-335.|[2]Olga Ab, et al. Activity of huC242-DM4, an antibody-cytotoxic agent conjugate, used in combination with anti-neoplastic agents against gastric cancer cells in culture. Mol Cancer Ther (2007) 6 (11_Supplement): A127.-CASNumber-868747-45-9-MolecularWeight-150000 (average)-Compound Purity-98.71-SMILES-[Cantuzumab ravtansine]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);Microtubule/Tubulin-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related